To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Summary
HB1492 would amend section 1192(e)(1)(A)(ii) of the Social Security Act to change the Drug Price Negotiation Program’s timing rules for certain prescription drugs. Specifically, it would replace the current 7-year negotiation period for small-molecule drugs with an 11-year period, matching the treatment already applied to biologic products. The bill is written to apply retroactively as if this change had been included in the Inflation Reduction Act (Public Law 117-169).
In practical terms, the measure would delay when certain small-molecule drugs become eligible for Medicare price negotiation, giving those products a longer period of market exclusivity before negotiation begins. The bill does not create a new program; it modifies an existing federal drug pricing provision in title XI of the Social Security Act and would affect manufacturers of prescription drugs, Medicare, and the federal agencies that administer drug price negotiations.
Impact
The bill would amend federal law governing the Medicare Drug Price Negotiation Program by extending the negotiation timeline for small-molecule drugs from 7 years to 11 years, aligning it with biologics. This would change the statutory timing in 42 U.S.C. 1320f-1(e)(1)(A)(ii) and would likely delay the point at which some drugs are subject to negotiated prices under Medicare. Because the amendment is stated to take effect as if included in Public Law 117-169, it would operate retroactively within the framework of the Inflation Reduction Act’s drug pricing provisions.
Sentiment
Based on the bill text and available legislative context, the measure appears to be introduced in a supportive, policy-driven effort by its sponsors to equalize treatment between small-molecule drugs and biologics. There is no recorded committee debate or vote history in the provided materials, so no formal opposition or bipartisan split is documented here. The sponsorship by members from both parties suggests at least some cross-party interest in the issue, but the overall sentiment in the available record is limited to introduction and referral.
Contention
The central point of contention is the policy choice to extend the negotiation delay for small-molecule drugs, which would benefit pharmaceutical manufacturers by preserving longer periods before Medicare negotiation but could postpone lower negotiated prices for beneficiaries and the program. Supporters are likely to frame the bill as correcting an imbalance between small-molecule drugs and biologics, while critics would likely argue it weakens Medicare’s drug price negotiation authority and could increase federal and beneficiary costs. No specific objections or amendments are recorded in the provided committee materials.